BetaListings are in beta: details come from the parties and are not independently verified. Read the disclaimer.
Raising$190m
StageSeed
RegionUK & Europe
Valuation
TractionPeer-reviewed data in Redox Biology (2024) and Blood (2020); patent family covering synthesis and therapeutic use; lead asset Ag5 for metastatic and brain cancers, second asset Au5 for invasive fungal pathogens.
The business
What it does
ARJUNA Therapeutics is a Europe-based biotech developing therapeutic molecular clusters, a new class of small-molecule medicine, led by Ag5, which targets mitochondrial antioxidants in metastatic and brain cancers and sensitises tumours to radiotherapy. A second asset, Au5, targets invasive fungal pathogens. The company holds patents on synthesis and therapeutic applications, with published data in Redox Biology (2024) and Blood (2020). It is raising $190m over five years in tranches of $10m, $80m and $100m to take the lead medicine into the clinic.
Members only
Login to see details
Sign in to see the summary, the evidence and use of funds for Arjuna Therapeutics. Membership is free.
We never publish contact details on the site. After approval the system will make an intelligent match.